What Is Adam O’Dell’s “x.AI” Stock Pick? (Revealed)

Investment guru Adam O’Dell recently released a presentation on the Money & Markets website about something he’s calling “x.AI” (“extreme AI”).

And according to O’Dell, he’s found “the No. 1 x.AI company” at the center of it all, a small-cap stock he believes is “set to skyrocket in the coming months and years ahead.”

What stock is he teasing?

Well, it turns out Adam O’Dell isn’t just bullish on one company.

He’s tracking THREE different “x.AI” stocks.

And while he didn’t reveal the name of these stocks in the presentation, I looked into his clues, and I think I’ve identified two of them, including his “No. 1” pick.

In this post, I’ll show you everything you need to know.

Overview of Adam O’Dell’s “x.AI” Prediction

Adam O’Dell’s “x.AI” presentation centers around artificial intelligence and how he believes “x.AI” will be the fastest-growing sector in the “$80 trillion AI industry.”

“x.AI is the fastest-growing sector in the booming $80 trillion AI industry.”

According to O’Dell, x.AI stands for “extreme AI,” and he calls it that because of the “extreme wealth” he claims this sector has the potential to create.

“That’s why I call it x.AI — which stands for extreme AI.

I call it this for no other reason than the extreme wealth this sector has the potential to create…”

Artificial intelligence is intelligence demonstrated by machines. And there are many ways in which this technology can help improve our lives. However, O’Dell’s prediction focuses mostly on how AI is being used to help us “live healthier, happier, longer lives.”

“And it’s easy to see why when you know what x.AI is focused on…

In short, it’s about enhancing the most valuable thing for each of the 7.9 billion people on planet Earth right now:

Our health, and the health of our loved ones.

As we speak, the smartest minds in the world are leveraging AI to help us live healthier, happier, longer lives.

With cures and treatments that go far beyond the limitations of modern medicine.”

During the presentation, O’Dell pointed out numerous examples of how AI is impacting the healthcare sector and the different types of innovations he is tracking.

For instance, he discussed how “fountain of youth” type medicines are being developed as a result of AI, how AI-related preventative treatments are being explored, and how AI is being used to develop “bloodless blood tests.”

However, the main innovation O’Dell focused on in the presentation is next-generation sequencing (NGS), which he claims his “No. 1 company” has pioneered.

“My No. 1 company has pioneered a new approach to genetic sequencing…

That is called next-generation sequencing. Or NGS for short.

NGS uses artificial intelligence to create what are called ‘multilayered artificial neural networks.'”

What is next-generation sequencing?

According to Wikipedia, next-generation sequencing, also known as “massive parallel sequencing,” relates to high-throughput approaches to DNA sequencing.

And as far as “multilayered artificial neural networks” go, O’Dell describes these networks as the “brain” behind DNA sequencing machines.

“Now, I know it’s a mouthful…

But you can think of these neural networks as the ‘brain’ that powers the machines used to sequence DNA.

Basically, they operate like the central processing unit of a computer, but much more powerful.

Scanning, analyzing and storing DNA information using data simulations so complex they were previously impossible…”

The science behind all of this is well beyond my area of expertise (lol), but my understanding of DNA sequencing is that it’s a process that involves “mapping out” the sequence of a DNA molecule. And I’ve noticed several stockpickers talking about this recently.

For instance, I recently wrote about Jeff Brown’s “Omnia” prediction, which centers around how DNA sequencing and synthetic biology are being used to disrupt the agriculture, energy, and manufacturing industries.

So this tech isn’t just being used in the healthcare sector; some of the ways in which companies are leveraging this technology are pretty mind-blowing.

In any case, Adam O’Dell focuses on how AI and DNA sequencing technology is being used to innovate the healthcare space, and he’s particularly bullish on one company.

Why? According to O’Dell, the company has developed “proprietary NGS technology” that allows them to build custom genetic sequencing tests with the help of “x.AI.”

“This company’s proprietary NGS technology, allows them to build customizable genetic sequencing tests…

That produce results much faster and cheaper than the old method.

Before NGS, scientist could only sequence one single DNA fragment at a time.

That’s why it took so long and cost so much.

But now, with the help of x.AI…

Scientists can use NGS to sequence MILLIONS of DNA fragments simultaneously.”

What’s his x.AI pick?

O’Dell hints at three companies in the presentation, and I believe I know what two of them are. In the next section, I’ll show you what I think he’s teasing and why.

What Are O’Dell’s 3 “x.AI” Stock Picks?

As expected, Adam O’Dell didn’t share his x.AI stock picks in the video. Instead, he shared clues about each company and details each pick in a research report that comes with a Green Zone Fortunes subscription. But as mentioned, I think I’ve found two of them.

Let’s start with his first pick…

Stock Pick #1 (Adam O’Dell’s “No. 1 x.AI company”)

Finding this stock wasn’t easy; I spent hours going through the clues O’Dell shared and came close to giving up. But eventually, I found a company that matches his clues.

It’s called Fulgent Genetics (ticker: FLGT).

And I believe this is O’Dell’s “No. 1 x.AI company.”

Why? Well, based on what we’ve discussed so far, we already know it’s a small-cap company (market cap of between $300 million and $2 billion) and that it uses NGS technology. He also said the company is in “the race to cure” heart disease, respiratory disease, and cancer.

But these clues weren’t enough to go off. So, to figure out what his stock pick was, I trawled through the following clues he shared in the presentation:

“My No. 1 x.AI company is backed by a billionaire tech entrepreneur…

With a history of successful business ventures and philanthropy around the world.

Including ties to my alma mater, West Virginia University.

To date, he’s founded three AI companies.

The second of which he sold back in 2017 for nearly a billion dollars…

That was around the same time, he took this third, x.AI company public.

But unlike other billionaire CEOs: Bill Gates, Jeff Bezos and Elon Musk…

This company’s founder likes to stay out of the limelight.

With his name only hitting headlines when he donates millions to scientific research…

Or when he pops up on the Forbes billionaire list.”

This set of clues was where I spent most of my time, and at first, it led me nowhere because the individual clues are still somewhat vague.

I started by looking into all the different NGS companies backed by billionaires, and my initial thought was that it might be Twist Bioscience because O’Dell pitched this in his Imperium Machine presentation, and two other well-known gurus have recently teased this stock.

But it didn’t match the “billionaire founder” clue.

So, after sifting through dozens of companies in the gene-sequencing space, I eventually stumbled across Fulgent Genetics, a small-cap stock that was publicly listed in late 2016.

And after seeing it met the above criteria, I started looking into who founded the company, a billionaire named Ming Hsieh, whose profile matches O’Dell’s hints down to a T.

Here’s an overview of why:

• Ming Hsieh is on the 2021 Forbes billionaire list.
• He donated $5.5 million to West Virginia University in 2007.
• Hsieh has founded three tech companies that each appear, in one way or another, to utilize artificial intelligence. The first company he founded was AMAX Technology. The second was Cogent Systems, which was acquired by 3M for $943 million. And the third is Fulgent Genetics.
• Aside from being a successful tech entrepreneur, Ming Hsieh is well known for philanthropic work, which is yet another match of what O’Dell said.

The only caveat to what I just said is that Cogent was sold in 2010, not 2017, as O’Dell states in the presentation. However, given how closely all the other clues match, this could be an error on O’Dell’s part or a mistake in the presentation’s transcript.

What does the company do?

I’m not an expert on what this company does or the science behind it, so I suggest doing your own research and drawing your own conclusions on this.

However, Fulgent Genetics is a California-based company that utilizes next-generation sequencing. That much is clear.

And according to the website, it “develops flexible and affordable genetic testing” and prides itself on “flexibility and customization.” So it seems to align with O’Dell’s clue about how his recommended company builds “customizable genetic sequencing tests.”

Also, some of the tests the company has developed include infectious disease and, in particular, cancer-related testing, which matches what O’Dell said in the presentation.

Oh, and according to this annual report, Fulgent Genetics’s technology is “powered by artificial intelligence and machine learning.”

So, long story short, I believe Fulgent Genetics is O’Dell’s top “x.AI” pick.

Either way, to find out if I’m right and get O’Dell’s research, it’s best to see the report he put together called “NGS Fortunes: The No. 1 x.AI Company Working to Eradicate Cancer.”

And as mentioned, the only way to access that report is to join Green Zone Fortunes. I’ll give you an overview of this service shortly, but for now, let’s look at his other two picks.

Stock Pick #2

Adam O’Dell’s second stock pick is a precision medicine company that he says provides treatments for rare diseases and blood disorders.

“This next company is a precision medicine company.

It provides drug treatments for rare diseases and blood disorders.

Precision medicine is another area of x.AI that uses information from a patient’s genes to prevent and diagnose disease.

It relies on AI’s ability to analyze a patient’s entire DNA.

Through what’s called ‘computational biology.’

And then it prescribes a custom treatment plan based on their genetic profile.”

Despite searching, I was unable to figure out what this stock is, but those are the main clues he shares. So if you do end up figuring it out, let me know in the comments below.

And the research report that corresponds with this pick is called “Precision Profits: The Tiny Company Creating the Blueprint for Personalized Drug Discovery.”

Stock Pick #3

O’Dell’s third AI stock pick is a biotech company that he says has developed its own AI technology to help identify HIV and infectious disease.

“Because this small biotech company has developed its own AI technology…

To perform target identification for HIV and infectious disease.”

Adam O’Dell also said that the company has clinical trials in place, that it did a deal for an HIV immunotherapy cure for $785 million, and that it’s “supported” by the Bill & Melinda Gates Foundation and the National Institutes of Health.

“This company also has several drugs in the FDA’s phase II and phase III clinical trials.

Plus, it has partnerships already in place with other, much larger biotech firms…

Including one for an HIV immunotherapy cure, which resulted in a $785 million deal.

And to top it off, it’s supported by the Bill & Melinda Gates Foundation…

As well as the National Institutes of Health.”

Aside from that, the only other clue he shared was that the company’s shares are trading for “less than $10.”

What could it be?

After looking into O’Dell’s clues and coming up with a few different possibilities, I ended up coming across this biospace.com article, which states that Gilead Sciences did a $785 million deal with Gritstone Oncology to develop an HIV cure.

From there, I looked into O’Dell’s other clues, and it looks like a match.

In short, Gritstone Oncology (ticker: GRTS) is a California-based biotech company that develops cancer and infectious disease-related treatments.

And according to the company website, Gritstone Oncology has developed an artificial intelligence-based platform called Gritstone EDGE™ to develop its immunotherapy.

What’s more, it’s a small-cap stock trading for under $10, and it appears to match the clues about the Bill & Melinda Gates Foundation and the National Institutes of Health.

So, this looks like O’Dell’s third pick.

And the details are contained in a report O’Dell created called “Tomorrow’s Edge: The x.AI Company Treating HIV and Infectious Disease.”

Who Is Adam O’Dell?

Adam O’Dell is the Chief Investment Strategist for Money & Markets, a Florida-based financial publishing company that sells several investment research services.

The main service O’Dell runs is called Green Zone Fortunes, and this is the service he’s pitching as part of the “x.AI” presentation. However, he also heads up at least three other advisories that I know of: Home Run Profits, Wednesday Windfalls, and 10X Profits.

The Money and Markets website states that O’Dell holds an MBA from the University of Phoenix and is a Chartered Market Technician (CMT), which means he knows what he’s doing when it comes to trading using technical analysis.

Most of the stocks I’ve seen O’Dell tease center around tech or biotech, but he has released many different “stock teaser” videos over the years.

The most recent one I wrote about is O’Dell’s “Infinite Energy” pitch, and I was able to identify four stocks he teased in that presentation, so you might find that worth checking out if you want to see what other stocks he’s tracking.

What Is Green Zone Fortunes? And Is It Legit?

Green Zone Fortunes is Adam O’Dell’s flagship stock advisory service, where he shares his latest stock picks and investment research with subscribers each month.

The cost of the service depends on which page on the Money and Markets site you join through, but as of writing, it costs $79 if you sign up through the x.AI presentation.

This gives you access to O’Dell’s top stock pick each month, the model portfolio, and a “Weekly Hotlist” of 10 stocks his “Green Zone Rating system” identifies each week.

Aside from this rating system, O’Dell says that he and his team use a strategy called Adaptive Investing™ to identify stocks with growth potential across market sectors.

And he shares his top ideas with subscribers. From there, you can decide if you want to follow his picks using your brokerage account.

Is it legit? Green Zone Fortunes isn’t a scam, it’s run by Adam O’Dell, who is a genuine expert, and it comes with a 12-month refund policy.

However, there’s no guarantee you’ll make money following his investment ideas. And as with any investment, it’s possible you could lose money.

If you want to know more, see my full review of Green Zone Fortunes. In it, I go into more detail on how the service works and what you get if you decide to join.

Bottom Line

The “x.AI” presentation is all about how O’Dell believes the “extreme AI” sector, which more or less represents the convergence of AI and DNA sequencing, will be the fastest-growing industry over the next ten years.

Based on the clues O’Dell shared in the presentation, I believe his “No. 1 x.AI company” is Fulgent Genetics. And while I’m not sure what his second pick is, I believe the third stock he teases in the presentation is Gritstone Oncology.

Of course, these are just my guesses, so I can’t guarantee I’m right. But if you want to find out for sure, all you need to do is join Green Zone Fortunes and see the reports I mentioned earlier since these come as part of the subscription.

Whatever you decide, I hope you found this helpful.